| *together with VantagePoint | Good day, 360! | Here are our top investing ideas today. And a special invitation to join Jeff for an open training Session Tues 2pm EST in the Alpha Chamber. His special ends tonight so give it a look below 👀. | | FOCUS LIST🔎 | SLXN - Up over 50% in the pre-market after PESG releases report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers | QNRX - Up over 25% in pre after insider share purchases by Co-Founders CEO and COO | ORCL - Up over 8% in pre after reporting strong earnings, powered by cloud and AI growth | | | | HOTLIST🔥 | SLXN - Up over 50% in the pre-market after PESG releases report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers | Silexion Therapeutics LTD (SLXN) is a biopharmaceutical company that discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. | Overnight, PESG Research released a report on Silexion Therapeutics titled Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers. The report highlights the company's impressive clinical achievements and unique approach alongside industry drivers including the increasing M&A activity in the space. | As a recently de-SPACed company following its merger with Moringa Acquisition Corp (NASDAQ: MACA), Silexion presents an interesting opportunity in the rapidly growing field of targeted cancer treatments, particularly in addressing the challenges of pancreatic and potentially other KRAS-driven cancers. | The stock traded up over 50% in the pre-market in reaction to the report. | | The $1.30 area acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $1.42, $1.50, $1.60, $1.70 and then the pre-market high at $1.80. Beyond that, $1.90 and $2.10 come into play. | Below $1.30, targets to the downside are $1.20, $1.05 and then a gap fill at $0.9799. | | | | | QNRX - Up over 25% in pre after insider share purchases by Co-Founders CEO and COO | Quoin Pharmaceuticals Ltd. (QNRX) is a clinical stage specialty pharmaceutical company that focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). | Late yesterday, it was reported that its Chief Executive Officer, Michael Myers, and Chief Operating Officer, Denise Carter, have recently made significant purchases of the company's American Depositary Shares (ADSs), signaling their confidence in the company's growth and direction. | On September 3 and 4, 2024, Michael Myers, CEO of Quoin Pharmaceuticals, acquired a total of 37,894 ADSs at prices ranging from $0.619 to $0.7974 per ADS. Similarly, COO Denise Carter acquired a total of 37,735 ADSs between September 3 and 4, 2024, at prices between $0.6253 and $0.7965 per ADS. | The stock traded up over 25% in the pre-market in reaction to the insider buys. | | The $1.10 area acted as support in the pre-market. | Above it, targets to the upside are $1.20, $1.30, $1.40, $1.50, $1.60 and then the pre-market high at $1.76. | Below $1.10, targets to the downside are $1, $0.90, and then a gap fill at $0.9799. | | ORCL - Up over 8% in pre after reporting strong earnings, powered by cloud and AI growth | Oracle Corporation (ORCL) offers products and services that address enterprise information technology environments worldwide. Its Oracle cloud software as a service offering include various cloud software applications, | In the after-hours, the company reported Q1 2024 financial results. | Highlights include: | Oracle's cloud services revenue rose 21% to $5.6 billion in the first quarter. Its overall revenue of $13.31 billion beat estimates of $13.23 billion. | Excluding items, the company earned $1.39 per share, above estimates of $1.32 apiece. | It also announced a partnership with Amazon Web Services yesterday, after having signed a similar one with Alphabet's Google Cloud in June. | The stock traded up over 8% in the pre-market in reaction to the results. | | The first target for bulls is the pre-market high at $153.75. | Beyond that, is new all-time highs and blue sky. | Below $153.75, targets to the downside are $150, $148, $146 and a gap fill at $139.89. | | MARKET NEWS 📰 | | | Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull | | DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer | *Sponsored content: We're a proud affiliate for VantagePoint, meaning if you click a link for a product or service, we may earn a commission at no extra cost to you. We believe in the companies we form affiliate relationships with, but please don't spend any money on these products or services unless you believe they will help you achieve your goals. | FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. | RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. | RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. | RagingBull.com, LLC shall be entitled to recover attorneys' fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys' fees, costs and disbursements in addition to any other relief to which it may be entitled. | WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. |
|
|
|
Post a Comment
Post a Comment